Local Vaginal Estrogen for Genitourinary Syndrome of Menopause
Genitourinary syndrome of menopause (GSM) is the dryness, burning, painful sex and urinary urgency that follow the drop in estrogen, and local low-dose vaginal estrogen is the treatment with the strongest evidence behind it. The 2025 AUA, SUFU and AUGS guideline states in its own words that local low-dose vaginal estrogen has the most robust evidence base of the GSM treatments. It is PRESCRIPTION ONLY. There is no self-start version of this and nothing on this page is a prescription. What this page gives you is what the evidence shows, what the treatment normally looks like, and the specific questions to take to a clinician. Educational only, not medical advice.
Get GSM named by a clinician instead of self-diagnosing it GSM is diagnosed on the symptom picture (dryness, burning, pain with sex, urinary urgency or frequency, recurrent urinary tract infections), with or without physical findings, once other causes are ruled out. Bring the urinary symptoms up explicitly, because they are the half most often left out of the conversation.
The urinary symptoms overlap almost completely with overactive bladder and with infection, and those get treated very differently. The wrong label here means months on the wrong treatment.
Clear the two hard stops with your clinician before anything is prescribed Any undiagnosed vaginal bleeding, and any postmenopausal bleeding, has to be worked up first. A personal history of breast cancer or another hormone-sensitive cancer needs your oncologist's input, particularly if you are on an aromatase inhibitor. Casperson's own published position is that women with a breast cancer history may still be able to use it but should clear it with their oncologist, because each person is different.
Bleeding can signal endometrial pathology, which needs finding before anything hormonal starts. Hormone-sensitive cancer care is individualized and belongs with the team already managing it.
Know what the starting phase normally looks like, so the prescription makes sense when you get it The usual pattern is nightly for the first two weeks or so, then a drop to maintenance. Typical US product labeling regimens are a 10 mcg estradiol vaginal insert nightly for 14 nights, or roughly 0.5 to 1 g of estradiol vaginal cream nightly for about two weeks. These figures come from product labeling, not from a trial, and your own prescription is the one that counts.
The loading phase is what gets the tissue back toward baseline: epithelial thickness, blood flow and pH. Spacing the doses out before that has happened is what makes people conclude it did not work.
Treat maintenance as permanent, not as a course you finish Maintenance is typically twice a week. Casperson's own written guidance is 1 g twice a week, measured as the length from fingertip to second knuckle, applied at night, with the applicator about halfway in rather than aimed at the cervix. Follow the instructions that come with your own prescription.
GSM is progressive, and it relapses when treatment stops, because the underlying estrogen loss has not changed. This is the single most common reason people cycle in and out of symptoms.
Ask about the other delivery forms if nightly then twice weekly does not fit your life A 2 mg estradiol vaginal ring worn continuously and changed every three months is one option; vaginal DHEA (prasterone) taken daily is another; inserts and cream are the others. Comparative reviews find the delivery forms similarly effective, so this is largely a preference decision to make with your prescriber.
Adherence is the thing that decides whether this works, and the form people will actually keep using beats the form that looks best on paper.
Ask specifically for the vaginal form, not an oral one Vaginal estrogen, not oral estrogen, is the form with evidence for preventing recurrent urinary tract infections after menopause. If recurrent UTIs are your main problem, name that as the goal in the conversation, because it changes which form is appropriate.
Restoring vaginal pH and the lactobacilli that depend on it is what reduces colonization by the bacteria that cause UTIs. That is a local effect, and an oral dose does not deliver it the same way.
Reassess at 8 to 12 weeks, and if nothing has changed, question the diagnosis rather than the dose Expect gradual improvement over weeks, not days. If there has been no change by 8 to 12 weeks, the useful next question is whether something else is also going on: a vulvar skin condition, pelvic floor dysfunction, or vestibulodynia. The guideline works on shared decision-making and does not mandate escalating the dose.
A partial or absent response is information. It usually means a second cause is sitting alongside the GSM, and chasing it with more estrogen will not find it.
Evidence check, does it work: this is the strongest evidence in GSM care The 2025 AUA, SUFU and AUGS guideline states that local low-dose vaginal estrogen has the most robust evidence base of the GSM treatments. That sits on top of a Cochrane review of randomized trials of local estrogen for vaginal atrophy and a separate systematic review of vaginal estrogen for GSM, both finding consistent symptom benefit across delivery forms.
Judged against the rest of menopause symptom care, this is an unusually settled question. Multiple randomized trials, a Cochrane review, and a current multi-society guideline all point the same way.
Evidence check, the boxed warning: real change, and observational data underneath it On 12 February 2026 the FDA announced approval of labeling changes removing the boxed-warning risk statements for cardiovascular disease, breast cancer and probable dementia from six menopausal hormone therapy products, a batch that explicitly includes topical vaginal estrogen therapy. Read that precisely: it is a rolling, product-by-product relabeling that began in November 2025, not a single blanket removal across every product on the shelf. The safety evidence underneath it is large observational cohort data, the Women's Health Initiative Observational Study and the Nurses' Health Study, not randomized trials of the low-dose vaginal products themselves.
Two things are true and both matter. The warning genuinely did not fit the low-dose local products, and the label is now catching up. And the reassurance rests on observational cohorts rather than randomized outcome trials, which is a B, not an A. The relabeling reduces a warning; it does not remove the need for a clinician to judge your individual case.
After menopause the tissue of the vulva, vagina, urethra and bladder trigone loses estrogen support.
View sources
Your Post Menopause Urethra, with Dr. Kelly Casperson (Dr. Streicher's Inside Information, S3 Ep162)
Vaginal Estrogen Explained: Safety, Benefits, and Options, with Dr. Kelly Casperson
Vaginal Estrogen, Kelly Casperson MD
The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause (Kaufman et al., Journal of Urology, 2025)
Local oestrogen for vaginal atrophy in postmenopausal women (Lethaby et al., Cochrane Database of Systematic Reviews, 2016)
Vaginal estrogen for genitourinary syndrome of menopause: a systematic review (Rahn et al., Obstetrics and Gynecology, 2014)
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society (Menopause, 2020)
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women (Perrotta et al., Cochrane Database of Systematic Reviews, 2008)
Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study (Crandall et al., Menopause, 2018)
Vaginal estrogen use and chronic disease risk in the Nurses' Health Study (Bhupathiraju et al., Menopause, 2019)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Independent curation. YourProtocol is an independent platform. This protocol is based on the publicly available work of Kelly Casperson and is not created, reviewed, endorsed by, or affiliated with Kelly Casperson or Urologist (MD); founder, The Casperson Clinic.
Is this for you
- Anyone whose dryness, burning or pain with sex started around or after menopause
- People with recurrent urinary tract infections after menopause who have never been offered the vaginal form
- Anyone who was frightened off vaginal estrogen by the boxed warning and wants to know exactly what changed in 2026
- People with a breast cancer history who want to know what the honest version of this conversation with an oncologist looks like
- Not for you as a self-start: this is prescription only, and there is no over-the-counter version of it
Cautions
- Local vaginal estrogen is PRESCRIPTION ONLY. Nothing on this page is a prescription, none of it is medical advice, and you should never start it on your own or use someone else's.
- Any undiagnosed vaginal bleeding, and any bleeding after menopause, has to be evaluated by a clinician before hormonal treatment of any kind starts.
- A personal history of breast cancer or another hormone-sensitive cancer needs your oncologist's input, particularly if you are taking an aromatase inhibitor. Kelly Casperson's own position is that it may still be possible, and that it is an oncologist's call, not a website's.
- Known or suspected pregnancy is a contraindication.
- New pelvic pain, unusual discharge or any bleeding while you are on treatment means stopping and being seen.
- The FDA's 2026 relabeling reduces a warning; it does not remove the need for individual clinical judgment, and it is a rolling product-by-product change rather than a blanket removal across everything on the shelf.
- Kelly Casperson has disclosable commercial interests, including her own DHEA vulvar serum product line, paid courses, a paid membership and a paid newsletter tier, and she points readers to a named third-party telehealth service whose commercial relationship with her we could not verify. None of the evidence on this page rests on her: it rests on the guideline, the Cochrane review and the cohort studies cited above.
- Educational only, not medical advice, and not a substitute for care from your own clinician.